ClinicalTrials.Veeva

Menu
P

Peters Medical Research | High Point, NC

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lubiprostone
Diclofenac
Oxycodone
Vibegron
PRC-4016
CIN-102
Vonoprazan
Naproxen
Famciclovir
Dapsone

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 63 total trials

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of K-645 in the Treatment of Multiple Migraine Attacks

This is a multicenter, randomized, double-blind, placebo-controlled, 3-period crossover study to evaluate the safety, tolerability, and efficacy of t...

Active, not recruiting
Acute Migraine
Drug: K-645 dose level 2
Drug: Placebo

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatme...

Active, not recruiting
Acute Migraine
Drug: Placebo
Drug: Elismetrep (K-304) Dose level 3

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Drug: Guselkumab Dose 2
Other: Placebo

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopa...

Enrolling
Idiopathic Gastroparesis
Drug: Placebo
Drug: CIN-102 Dose 15mg

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Active, not recruiting
Diabetic Gastroparesis
Drug: Placebo
Drug: CIN-102 Dose 15mg or 10mg

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine

The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with...

Enrolling
Irritable Bowel Syndrome with Diarrhea
Drug: CIN-103
Drug: Placebo

Trial sponsors

Ferring logo
Ironwood Pharmaceuticals logo
Apnimed logo
C
Exact Sciences Corporation logo
I
K
M
Phathom Pharmaceuticals logo
P

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems